Bi-directional regulation between NAD/NAMPT and IFN-gamma/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.
Targeting metabolic and immune pathways together may help melanoma patients who don't respond to standard immunotherapy.
This mechanistic study in metastatic cutaneous melanoma uncovers a bidirectional regulation between NAD metabolism (NAMPT) and the IFN-gamma/PD-L1 immune checkpoint axis through BRD4/IRF1 and mitochondrial respiration. The findings suggest dual targeting of metabolic and immune pathways as a strategy to overcome ICI resistance in advanced melanoma.
What the study was
- Study design
- Mechanistic/preclinical study
- Population
- Metastatic cutaneous melanoma (cell lines and likely patient samples)
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Journal of Experimental and Clinical Cancer Research
Why it surfaced
Mechanistic melanoma study with ICI resistance implications — preclinical novelty but low population reach at current stage. At lower threshold of STANDARD.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.